Atherogenic risk factors, such as hypercholesterolemia, are associated with increased risk of neurodegeneration, especially Alzheimer's dementia. Human plasma electronegative low-density lipoprotein [LDL(À)], especially L5, may serve as an important contributing factor. L5 promoting an inflammatory action in atherosclerosis has been extensively studied. However, the role of L5 in inducing neuroinflammation remains unknown. Here, we examined the impact of L5 on immune activation and cell viability in cultured BV-2 microglia. BV-2 cells treated with lipopolysaccharide or human LDLs (L1, L5, or oxLDL) were subjected to molecular/ biochemical assays for measuring microglial activation, levels of inflammatory factors, and cell survival. A transwell BV-2/N2a coculture was used to assess N2a cell viability following BV-2 cell exposure to L5. We found that L5 enables the activation of microglia and elicits an inflammatory response, as evidenced by increased oxygen/nitrogen free radicals (nitric oxide, reactive oxygen species, and peroxides), elevated tumor necrosis factor-a levels, decreased basal interleukin-10 levels, and augmented production of pro-inflammatory proteins (inducible nitric oxide synthase and cyclooxygenase-2). L5 also triggered BV-2 cell death primarily via apoptosis. These effects were markedly disrupted by the application of signaling pathway inhibitors, thus demonstrating that L5 interacts with Toll-like receptor 4 to modulate multiple pathways, including MAPKs, PI3K/Akt, and NF-jB. Decreased N2a cell viability in a transwell co-culture was mainly ascribed to L5-induced BV-2 cell activation. Together, our data suggest that L5 creates a neuroinflammatory stress via microglial Toll-like receptor 4, thereby leading to the death of BV-2 microglia and coexistent N2a cells. Atherogenic L5 possibly contributes to neuroinflammation-related neurodegeneration.
Neuroinflammation is implicated as a pathogenic mechanism of neurodegeneration, including Alzheimer's disease (AD), and AD often shows comorbidity with cardiovascular diseases (CVDs) (Casserly and Topol 2004; Stampfer 2006) . Epidemiological studies determined that older adults with CVDs other than stroke have a higher risk of dementia and AD than those without CVDs. The highest risk occurs in people with peripheral arterial disease, suggesting that extensive peripheral atherosclerosis is a risk factor for AD (Newman et al. 2005) . Studies have reported that patients suffering from CVDs, such as atherosclerosis, show alterations in immunologic markers, including increased pro-inflammatory cytokine activity and inflammation-related proteins (Casserly and Topol 2004; Galkina and Ley 2009) . Also, peripheral chronic inflammation gives rise to changes in brain structure and synaptic plasticity that lead to cognitive decline and Alzheimer's dementia. Hypercholesterolemia contributes to neuroinflammation, accelerates cerebral degenerative changes, and is a risk factor for AD (Luchsinger and Mayeux 2004) . Although a close relationship between hypercholesterolemia and AD has been demonstrated epidemiologically, the contribution of this CVD risk factor to neurodegenerative pathogenesis is not fully understood.
Using statins to reduce plasma low-density lipoproteincholesterol (LDL-C) levels has a positive impact on dementia, suggesting a critical role of circulating LDL in the pathogenesis of dementia (Kuller 2007) . Cholesterol-based studies found a negative correlation between LDL-C levels and cognition (Taylor and MacQueen 2007; Lai et al. 2011) , and a high LDL-C level led to a faster cognitive decline in AD patients (Helzner et al. 2009 ). LDL causes atherosclerosis via endothelium dysfunction, inflammation, and a procoagulant vascular surface. Thus, atherosclerotic patients are at risk of neurodegeneration if LDL impairs cerebrovascular endothelium, invades neural milieu, and induces neuroinflammation. Actually, oxidized LDL (oxLDL) has been indicated to contribute to neurodegeneration via interactions with bamyloid proteins (Schulz et al. 2007) . It has been increasingly emphasized that plasma LDL elevates the prevalence of cognitive impairment and AD; however, the mechanism of LDL-mediated effects on dementia remains ill-defined.
Considering that LDL leads to atherosclerosis and positively correlates with the incidence of cognitive decline and AD, electronegative LDL [LDL(À)], a modified LDL found in human circulation, may be an important contributing factor. LDL(À) is a class of naturally occurring atherogenic lipoproteins (Sanchez-Quesada et al. 2004) . Among five subfractions (L1-L5) of human LDL, L5 has the highest electronegativity and is the only subfraction that elicits marked atherogenic changes and endothelial cell apoptosis (Chen et al. 2003; Lu et al. 2009 ). Moreover, elevated plasma L5 levels are found in asymptomatic individuals with increased cardiac risks, including hypercholesterolemia, type 2 diabetes, and metabolic syndrome (Chen et al. 2007) . Although the relevance of high cardiovascular risk to the increased plasma L5 is well understood, the role of L5 in the neurodegenerative progression remains unclear. Like oxLDL, L5 promotes a global inflammatory effect in atherosclerosis (Estruch et al. 2013c) ; however, it is unknown so far whether L5 also elicits neuroinflammation. Studies are needed to assess the impact of leaked plasma L5 on microglial reactivity in cases of cerebrovasculature disruption mediated by cerebral amyloid angiopathy or compromised blood-brain barrier (BBB) integrity induced by vascular factors related to atherosclerosis (Blennow et al. 1990; Kalaria 1999; Bell and Zlokovic 2009) .
We hypothesized that L5 induces neuroinflammation, thereby leading to neural cell damage. Thus, the purpose of this study was to determine whether L5 impacts on microglial BV-2 cell reactivities in vitro, such as immune activation and viability. Inflammatory factors, cell death modes, and signaling cascades were assessed after the desired treatments. We found that L5, via Toll-like receptor 4 (TLR4), creates an inflammatory stress and causes BV-2 cell apoptosis. In transwell BV-2/Neuro-2a (N2a) cocultures, N2a cell injury was ascribed to L5-activated BV-2 cells. Here, we uncovered the truth of L5 stimulating neuroinflammation, thereby supporting the possibility that atherogenic L5 contributes to neurodegeneration.
Materials and methods
Chemicals, antibodies, and reagents All chemicals were from Sigma-Aldrich (Saint Louis, MO, USA) unless stated otherwise. tumor necrosis factor-a (TNF-a) and interleukin-10 (IL-10) ELISA kits, and lectin-like oxidized LDL receptor-1 (LOX-1, AB_354863) antibody were purchased from R & D Systems (Minneapolis, MN, USA). An annexin-V-fluoresceinisothiocyanate (FITC) apoptosis detection kit was purchased from Affymetrix eBioscience, Inc. (San Diego, CA, USA). Antibodies, including phospho-c-Jun N-terminal kinase (pJNK, AB_823588), pp38 (AB_2139682), pAkt (AB_329825), JNK (AB_2141027), p38 (AB_330713), Akt (AB_329827), inducible nitric oxide synthase (iNOS, AB_1078202), and cyclooxygenase-2 (COX-2, AB_ 2571729) were purchased from Cell Signaling Technology (Beverly, MA, USA). Glyceraldehyde 3-phosphate dehydrogenase (AB_627679) antibody and BAY11-7082 agent were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Horseradish peroxidase-conjugated secondary antibodies were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA, USA). 2 0 7 0 -Dichlorodihydrofluorescein diacetate and dihydrorhodamine-1,2,3 were purchased from Molecular Probes (Invitrogen, Carlsbad, CA, USA). PD98059, SP600125, SB203580, and LY294002 agents were purchased from Selleckchem (Houston, TX, USA). TAK-242 and caffeic acid phenylethyl ester were purchased from Cayman Chemical (Ann Arbor, MI, USA). All culture reagents were obtained from Gibco-BRL/Invitrogen (Carlsbad, CA, USA).
Availability of LDL particles
Human plasma LDL particles, including oxLDL, L1, and L5, were used in this study. Initially, blood samples were collected from hypercholesterolemic patients (diagnosed by physicians). Patients were admitted through the clinic of the Kaohsiung Medical University (KMU) Hospital. All participants provided written consent, and ethics committees (Institutional Review Board of KMU Hospital) reviewed and approved the consent procedure. LDL particles were prepared at and offered by Lipid Science and Aging Research Center (LSARC) of KMU, Kaohsiung, Taiwan. LDL isolation and subsequent separation of LDL subfractions were done using sequential potassium bromide density centrifugation and anion-exchange fast protein liquid chromatography system, respectively. Please see Appendix S1 for details.
Cell cultures and establishment of co-cultures
The mouse microglial BV-2 and neuroblastoma N2a cell lines were grown and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, and 1% penicillin/ streptomycin at 37°C in a humidified atmosphere of 95% air/5% CO 2 . All cultures were passaged twice each week by trypsinization and observed microscopically. Cell medium was replaced with serum-free DMEM/Nutrient Mixture F-12 containing GlutaMAX TM and antibiotics when being used for a series of experiments. For co-culture of BV-2 plus N2a, initially BV-2 cells (1 9 10 4 cells/cm 2 ) were seeded in the upper chambers (inserts) of 24-well transwell plates (pore size = 0.4 lm; Corning Inc., Tewksbury, MA, USA), while N2a cells (1 9 10 4 cells/cm 2 ) were seeded in separate 24-well plates. After 24 h of attachment, the inserts and separate 24-well plates were combined together to create the co-cultured system comprising BV-2 and N2a cells residing separately at upper and lower chambers. Using a transwell apparatus, both cell lines communicate with each other through the semipermeable membrane without direct cell contact. Cell media were replaced with serum-free DMEM/F-12 before the treatment of BV-2 cells with lipopolysaccharide (LPS), LDL, or chemical inhibitors for the assessment of N2a cell survival.
Cell survival assay
Trypan blue exclusion assay was used to determine the number of viable cells. Additionally, 3-(4, 5-dimethylthianol-2-yl)-2, 5-diphenyltetrazolium bromide reduction serving as an indicator of cellular metabolic activity was also used. Please see Appendix S1 for details.
Measurement of nitrite accumulation
The production of nitric oxide (NO) was determined by measuring nitrite, a stable oxidation product of NO. The extent of nitrite released into the media was detected by a spectrophotometric assay based on the Griess reaction. Please see Appendix S1 for details.
Determination of intracellular oxygen free radicals
To detect reactive oxygen species (ROS) intracellularly, a cellpermeable fluorogenic probe 2 0 7 0 -dichlorodihydrofluorescein diacetate was used for the determination. Also, another fluorogenic probe, dihydrorhodamine-1,2,3, was used for the detection of ROS, especially peroxide and peroxynitrite. Please see Appendix S1 for details.
Enzyme-linked immunosorbent assay
The amount of mouse TNF-a or IL-10 released from cells into the culture supernatant was determined by ELISA kits according to the manufacturer's instructions.
Morphological analysis of nuclei
To visualize apoptotic nuclei, cells were stained with 4 0 , 6-diamidino-2-phenylindole (1 lg/mL). Labeled cells were examined using an inverted fluorescence microscope equipped with an ultraviolet filter. Please see Appendix S1 for details.
Assessment of apoptosis by flow cytometric analysis
Cell death mode was determined by an annexin-V-FITC apoptosis detection kit that stains cells with annexin-V conjugated with FITC and propidium iodide, which was followed by fluorescenceactivated cell sorting. Please see Appendix S1 for details. 
Western blotting analysis

Statistical analysis
Data are expressed as the mean AE SEM from the indicated number of independent experiments. Statistical significance between multiple groups was analyzed by ANOVA, followed by Dunnett's test or Bonferroni's t-test. Student's t-test was used to evaluate differences between two groups. Analysis was performed using the SigmaStat version 4.0 software from Jandel Scientific (San Diego, CA, USA). The probability value less than 0.05 (p < 0.05) was considered statistically significant.
Results
L5 activates BV-2 microglia and induces an inflammatory response Initially, we examined whether L5 stimulates microglial activation and inflammation in BV-2 cells. Three experimental controls were included. L1 and oxLDL served as negative and positive controls, respectively. Contrary to L5, L1 is a naturally occurring lipoprotein in human blood; also, L1 is the least negatively charged LDL subfraction and considered to be of no cytotoxicity (Sanchez-Quesada et al. 2004; Estruch et al. 2013c) . OxLDL is a toxic lipoprotein that has pro-inflammatory properties and leads to immunocyte activation and inflammation in atherosclerotic lesions (Virella et al. 2002) . LPS was used as a second positive control because of its well-known induction of neuroinflammation by triggering microglial activation and the production of various inflammatory factors (Qin et al. 2007; Cunningham 2013) .
Various chemical parameters related to inflammatory induction were examined (Fig. 1) . Like LPS and oxLDL, L5 effectively induced the production of oxygen/nitrogen free radicals, including NO, ROS, and peroxides ( Fig. 1a-c) , whereas L1-treated cells and the untreated control showed no significant changes. For the secretion of cytokines, for example, TNF-a and IL-10, LPS, L5, and oxLDL but not L1 evidently increased TNF-a levels ( Fig. 1d) , which highlights the pro-inflammatory nature of L5. Except LPS, all used LDLs clearly decreased IL-10 levels when compared with the basal level of untreated control ( Fig. 1e ), suggesting that oxidatively or electronegatively modified LDL may suppress anti-inflammatory factors in order to elevate pro-inflammatory response. Further, cellular activation is essential for responding to external stimuli and often characterized by protein neosynthesis or elevated enzyme activity, which accelerates and amplifies biochemical reactions intracellularly; hence, two Fig. 1 An inflammatory response is induced in L5-activated BV-2 microglia. After treating with lipopolysaccharide (LPS) (1 lg/mL) or different low-density lipoproteins (LDLs) (30 lg/mL), including L1, L5, and oxLDL (OxL), for 24 h, cultures were subjected to assays for nitric oxide production (a), the intracellular formation of reactive oxygen species (b) and peroxides (c), and the secretion of tumor necrosis factor-alpha (TNF-a) (d) and interleukin-10 (e). Alternatively, cultures treated for 24 or 48 h, as indicated, were subjected to western blotting to detect inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) protein expression, as presented by representative blots (f). GAPDH served as a protein loading control. Western blot band intensity of iNOS and COX-2 was quantified using densitometry followed by normalization to the corresponding GAPDH level and the results are expressed in a histogram (g and h). Untreated cultures were used as a control (Ctl). Data are presented as the mean AE SEM from at least three individual experiments performed in triplicate. *p < 0.05 versus control. RFI: relative fluorescence intensity. inducible proteins, iNOS and COX-2, were assessed. Actually, increased expression of both iNOS and COX-2 closely correlates with neuroinflammation-related microglial activation (Qin et al. 2007 ). Thus, these two pro-inflammatory proteins were used as a surrogate marker for microglial activation. Like LPS and oxLDL, L5 elicited a noticeable increase in both iNOS and COX-2 levels when compared with untreated control; as expected, no detectable expression of either protein was observed in cultures exposed to L1 up for 48 h ( Fig. 1f-h ). These results suggest that BV-2 microglia respond to L5 stimulation, thus being reactively activated and producing pro-inflammatory proteins, oxygen/nitrogen free radicals, and cytokines.
L5 causes BV-2 gliotoxicity primarily through apoptosis
Previous studies reported that L5 is toxic to cardiomyocytes and endothelial cells and triggers apoptosis (Lu et al. 2009; Lee et al. 2012) . To investigate the cytotoxic role of L5 in glia, we assessed the survival of cultured BV-2 microglia exposed to L5. Both trypan blue exclusion and 3-(4, 5-dimethylthianol-2-yl)-2, 5 diphenyltetrazolium bromide reduction assays consistently showed that L5, oxLDL, and LPS markedly decreased the viability of BV-2 cultures when compared with the untreated control, whereas L1 exposure did not affect the cultured cells ( Fig. 2a and b) , which points out that both L5 and oxLDL are toxic to BV-2 microglia and competently induce gliotoxicity. Using annexin-V-FITC/ Fig. 2 L5 damages BV-2 microglia primarily via apoptosis. Following treatment with lipopolysaccharide (LPS) (1 lg/mL) or different lowdensity lipoproteins (30 lg/mL) for 24 or 48 h, cultures were subjected to a trypan blue exclusion assay as a measure of cell viability (a). Alternatively, cultures were treated for 24 h and then subjected to an 3-(4, 5-dimethylthianol-2-yl)-2, 5 diphenyltetrazolium bromide reduction assay and flow cytometry to determine the loss of viable BV-2 microglia (= gliotoxicity) (b) and cell death mode (c), respectively. Untreated cultures were used as a control. The mode of cell death was identified by staining with annexin-V-fluorescein-isothiocyanate (FITC) and propidium iodide using an apoptosis detection kit followed by fluorescence-activated cell sorting (FACS). In FACS plots, B1, B2, B3, and B4 represent the quadrants for necrotic, late apoptotic, viable, and early apoptotic cells, respectively. The histogram shows the cell percentage (% of total cells) in each quadrant for each treatment group. Data are presented as the mean AE SEM from at least three individual experiments performed in triplicate. *p < 0.05 versus control.
propidium iodide staining combined with flow cytometric analysis, we found that L5 but not L1 exerted gliotoxicity mostly via apoptosis with a minor induction of necrosis (living: 74.4%; apoptosis: 19.5%; necrosis: 6.1%), nearly resembling the cell death pattern induced by LPS (living: 68.6%; apoptosis: 19.8%; necrosis: 11.6%) but not oxLDL (living: 60.2%; apoptosis: 17.4%; necrosis: 22.4%) (Fig. 2c) . In a morphological analysis of nuclei using 4 0 ,6-diamidino-2-phenylindole staining, the characteristics of apoptosis (e.g., dense chromatin condensation and nuclei fragmentation) was observed in BV-2 cultures exposed to LPS, L5, and oxLDL, but not L1 ( Figure S1 ). These data suggest that L5 injures BV-2 microglia and exerts gliotoxicity primarily through apoptotic death. Linking to the results of Fig. 1 , L5-activated BV-2 microglia create an inflammatory stress that leads to their own death.
L5 induces inflammation and gliotoxicity through differently activating MAPKs, PI3K/Akt, and NF-jB in BV-2 microglia To examine the signaling cascades involved in L5-induced inflammation and gliotoxicity in BV-2 microglia, a variety of signaling pathway inhibitors were utilized: BAY11-7082 (BAY, inhibitory kappa B kinase inhibitor), PD98059 (PD, MEK/extracellular signal-regulated kinase (ERK) inhibitor), SP600125 (SP, JNK inhibitor), SB203580 (SB, p38 inhibitor), and LY294002 [LY, phosphoinositide 3-kinase (PI3K) inhibitor]. Following treatments, several chemical parameters were determined to assess which signaling cascades modulate L5-induced inflammation. When compared with L5 treatment alone, there were six major findings: (i) SP, SB, PD, and LY effectively reduced L5-induced NO production (Fig. 3a) ; (ii) only SP significantly decreased L5-induced intracellular ROS formation (Fig. 3b) ; (iii) both SP and PD obviously diminished intracellular peroxides induced by L5 (Fig. 3c) ; (iv) all inhibitors markedly reduced L5-induced TNF-a secretion (Fig. 3d) ; (v) SB notably enhanced the L5-induced decrease in basal IL-10 level (Fig. 3e) ; and (vi) SP, SB, PD, and LY clearly blocked L5-induced iNOS expression, while SB and LY markedly suppressed L5-induced COX-2 expression (Fig. 3f) . Similar to the efficacy of BAY, caffeic acid phenylethyl ester (nuclear factor kappa B, NF-jB inhibitor) was ineffective against L5-induced inflammation, except TNF-a ( Figure S2 ). These results offer several key insights into the pathways involved in L5-induced inflammation (Table S1 ): (i) L5 triggers the production of oxygen/ nitrogen free radicals primarily via MEK/ERK and JNK; (ii) L5 induces TNF-a secretion via multiple pathways, including MAPKs, PI3K, and NF-jB; (iii) blocking p38 signaling enhances the L5-induced decline in IL-10; and (iv) only p38 or PI3K mediates L5-induced joint expression of iNOS and COX-2. Together, these data suggest that ERK, JNK, p38, and PI3K are predominant pathways mediating most of L5-induced inflammatory effects, while NF-jB shows a minor involvement.
We next examined the effect of these inhibitors on L5-induced BV-2 cell death. Not PD and BAY, but SP and LY noticeably blocked L5-induced decrease in cell viability; oppositely, such cell survival decline was significantly enhanced by SB ( Figure S3 and Fig. 4a) . Also, in morphological analysis of apoptotic nuclei, the extent of L5-induced BV-2 cell apoptosis was relieved by SP and LY, but elevated by SB (Fig. 4b and c) . The death profile was further validated by flow cytometry which showed that SP and LY attenuate both apoptosis and necrosis, whereas SB augments the percentage of L5-treated BV-2 cells in late apoptosis ( Figure S4 ). Therefore, these results suggest that activated JNK or PI3K, which promotes pro-inflammation in L5-treated BV-2 cells, leads to microglial apoptosis, while p38 activation has a dual role in mediating pro-inflammatory and anti-apoptotic processes.
Not LOX-1 but TLR4 mediates L5-induced inflammation and gliotoxicity in BV-2 microglia We next explored BV-2 cell surface receptor that mediates L5-induced inflammation and gliotoxicity. LOX-1 is an oxLDL receptor, and it has been suggested that it recognizes L5 (Estruch et al. 2013c) . After binding to LOX-1, L5 induces several biological effects in endothelial cells, including apoptosis and the release of cytokines and chemokines (Tai et al. 2006; Lu et al. 2009; Lee et al. 2012) . To block LOX-1 signaling in BV-2 cells, a neutralizing anti-LOX-1 antibody was used. As shown in Figure S5 (a), oxLDL-induced up-expression of iNOS and COX-2 was inhibited by this neutralizing antibody, implying that blocking oxLDL/LOX-1 interaction suppresses oxLDL-induced microglial activation and inflammation. Also, the neutralizing antibody effectively decreased oxLDL-induced BV-2 gliotoxicity ( Figure S5b) . Unfortunately, the anti-LOX-1 antibody showed no effect against L5-induced inflammatory episodes in BV-2 cultures, including inducible iNOS and COX-2 expression, NO production, and cell death (Figure S5c-e). These results clearly suggest that L5-induced inflammation or gliotoxicity in BV-2 microglia does not depend on LOX-1 and another cell surface receptor is likely responsible for L5 binding.
Given that LOX-1 is not responsible for L5 transmission on BV-2 cell surface, we assessed the role of TLR4 which recognizes LPS and is activated by modified LDLs (Chavez- Sanchez et al. 2010b; Estruch et al. 2013c) . Moreover, TLR4 cooperates with CD14 to mediate cytokine release induced by LDL(À) in monocytes (Estruch et al. 2013a) . To examine the possibility that L5 induces inflammation and BV-2 cell death via TLR4, a TLR4 signaling inhibitor TAK-242 (TAK) is used. As shown in Fig. 5(a) , TAK (≥ 0.1 lM) obviously attenuated both iNOS and COX-2 levels in LPStreated BV-2 microglia, indicating that TAK is exactly effectual in blocking TLR4 signaling and inhibiting LPSinduced inflammation. Regarding the inflammatory responses induced by L5, TAK (0.5 and 5 lM) effectively disrupted L5-stimulated BV-2 cell activation, as evidenced by the lack of L5-induced up-expression of iNOS and COX-2 in the presence of TAK (Fig. 5b) . All other L5-induced effects involved in pro-inflammation, including increased production of oxygen/nitrogen free radicals (NO, ROS, and peroxides), elevated secretion of TNF-a, and decreased IL-10 release, were also completely abolished by TAK (Fig. 5c-g ). Moreover, L5-induced phosphorylation of JNK, p38, and Akt was evidently suppressed by TAK, indicating that the binding complex of L5/TLR4 signals to and activates JNK, p38, and Akt pathways (Fig. 5h-j) . Therefore, these data explicitly suggest that L5 induces the activation of TLR4-downstream pathways, including JNK, p38, and Akt, to trigger an inflammatory response.
Additionally, TAK effectively prevented BV-2 microglia from L5-induced gliotoxicity (Fig. 6a) . Such rescue was achieved by reducing apoptosis, as demonstrated by a decreased cell percentage representing apoptotic characteristics when comparing TAK plus L5 to L5 alone ( Fig. 6b and  c) . Furthermore, L5-induced early/late apoptosis (L5: 19.4% vs. TAK+L5: 2.1%) and necrosis (L5: 6.1% vs. TAK+L5: 0.6%) were evidently reduced by TAK, analyzed by flow cytometry (Fig. 6d and e) . These results suggest that microglial TLR4 mediates the effect of L5 on inflammation. Notably, blockade of L5-induced BV-2 cell activation and Fig. 3 Signaling pathway inhibitors diversely block the production of nitric oxide (NO), oxygen free radicals, cytokines, and pro-inflammatory proteins in cultured BV-2 microglia. Cultures were treated with or without various inhibitors, including SP600125 (SP, 5 lM), SB203580 (SB, 10 lM), PD98059 (PD, 10 lM), LY294002 (LY, 5 lM), and BAY11-7082 (BAY, 5 lM), for 1 h, followed by L5 (30 lg/mL) for 24 h. Untreated cultures were used as a control. After harvest, cultures were subjected to assays for NO production (a), the intracellular formation of reactive oxygen species (b) and peroxides (c), the secretion of tumor necrosis factor-alpha (TNF-a) (d) and interleukin-10 (e), and inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression (f). To quantitate iNOS and COX-2 proteins, the expression level relative to the untreated control (assigned a value of 1) was obtained using densitometry, followed by normalization to the corresponding GAPDH level. The quantitative values are shown below the representative blots. Data are presented as the mean AE SEM from at least three individual experiments performed in triplicate. *p < 0.05 versus L5. RFI: relative fluorescence intensity.
inflammation by TAK coincides with the decline in apoptotic and necrotic death. Thus, L5/TLR4-induced inflammation is a toxic stress that decreases the survival of BV-2 cells.
L5-activated BV-2 microglia create a neuroinflammatory stress that injures N2a cells
Since L5-induced activation in BV-2 microglia forms an inflammatory stress that injures themselves, we wondered whether L5-activated BV-2 cells produce neuroinflammatory conditions that damage N2a cells. To examine this issue, a transwell co-culture system of BV-2/N2a cells was employed (Fig. 7a) . Treating BV-2 cells with LPS, L5, and oxLDL but not L1 markedly reduced the survival of co-cultured N2a cells (Fig. 7b) . These data combined with the results shown in Fig. 1 suggest that L5-induced inflammation in BV-2 microglia is toxic to nearby N2a cells. Further, SP, SB, or LY effectively attenuated the N2a cell damage in L5-treated BV-2/N2a co-cultures (Fig. 7c) , suggesting that JNK, p38, or PI3K mediates L5-induced inflammation in BV-2 cells and/ or plays a pro-death role in N2a cells. Because L5 directly injured N2a cells ( Figure S6a ) and added L5 likely passed through transwell membrane, the decreased N2a cell viability in the transwell co-cultures might result from L5 alone and inflammatory factors secreted by L5-activated BV-2 cells. Of note, TAK almost completely suppressed L5-induced decrease in co-cultured N2a cell viability (Fig. 7d) , but not the survival decline in L5-treated N2a cultures ( Figure S6b) , implying that N2a cell damage in the transwell BV-2/N2a cocultures is primarily ascribed to L5-induced BV-2 cell activation and inflammation, while direct toxicity of L5 to co-cultured N2a cells is minor. Overall, these data suggest that N2a cells are directly susceptible to L5-induced neurotoxicity and L5-activated BV-2 microglia create a neuroinflammatory stress that injures coexistent N2a cells.
Discussion
Patients with atherosclerosis are at high risk for central nervous system (CNS) diseases, especially AD; moreover, inflammation in the co-pathogenesis of atherosclerosis and AD has been emphasized (Casserly and Topol 2004; Stampfer 2006 ). This implies that atherogenic risk factors promote brain inflammation that results in AD progression. Given that high LDL-C is a shared risk factor for atherosclerosis and AD, plasma LDL(À) is considered because its elevation contributes to the inflammation in atherosclerosis (Stampfer 2006; Estruch et al. 2013c) . A compromised BBB occurs as the partial pathology of AD and atherosclerosis (Kalaria 1999 ). Possibly, microglia, which dominate inflammation-related neurodegeneration, respond to leaked LDL(À) and injure neurons by secreting various inflammatory factors. In this study, we proposed a novel idea that L5-activated BV-2 microglia create a neuroinflammatory stress via TLR4 signaling, in turn leading to microglial apoptosis and reducing viability of coexistent N2a cells (Fig. 8) .
Microglia do not contact L5 under normal physiological conditions because L5 is not present in clinically healthy individuals with normal lipidemia. However, increased plasma L5 (up to 5-6% of LDL) in patients with increased cardiac risks (e.g., hypercholesterolemia, active smoking, type 2 diabetes, and metabolic syndrome) has been demonstrated; then, maybe L5 occurs in the CNS because of BBB dysfunction. In hypertensive patients suffering from hemorrhagic stroke, as well as under a pathological BBB leakiness resulting from vascular factors linked to hypertension, atrial fibrillation, and aortic and carotid atherosclerosis (Blennow et al. 1990) , plasma L5 by any chance passes through broken cerebrovasculature or injured BBB to initiate brain inflammation. Also, cerebrovascular dysfunction plays a critical role in Alzheimer's dementia. Cerebral amyloid angiopathy, which results from impaired clearance of Ab from the brain, Cultures were pre-treated with or without TAK at various concentrations (lM) as indicated for 1 h and then incubated with lipopolysaccharide (LPS) (1 lg/mL) for another 24 h. Western blotting was performed to detect inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expression induced by LPS (a). Alternatively, cultures pre-treated with or without TAK (0.5 or 5 lM) for 1 h were incubated with L5 (30 lg/mL) for 24 h. A series of assays were conducted to determine the iNOS and COX-2 expression (b), Nitric oxide production (c), the intracellular formation of reactive oxygen species (d) and peroxides (e), and the secretion of tumor necrosis factor-a (f) and interleukin-10 (g). GAPDH served as a protein loading control. Untreated cultures were used as a control. Quantitative values of iNOS and COX-2 proteins are shown below the representative blots (a and b). Furthermore, cultures treated with or without TAK (5 lM) for 1 h and then incubated with L1 or L5 (30 lg/mL) for 12 h, as indicated, were subjected to western blotting to detect the phosphorylation levels of JNK, p38, and Akt. The representative blots are presented and the histograms show the quantitative results of pJNK (h), pp38 (i), and pAkt (j) relative to the untreated control (assigned a value of 1). Data are presented as the mean AE SEM from at least three independent experiments performed in triplicate. *p < 0.05 versus control. can severely disrupt the integrity of cerebral blood vessel wall (Bell and Zlokovic 2009 ). An increased cerebrospinal fluid/serum albumin ratio is found in AD patients, particularly those with peripheral vascular disease (Blennow et al. 1990; Hampel et al. 1995) , suggesting BBB breakdown in AD etiology and pathogenesis. Brain imaging studies indicate that disturbed BBB function precedes cognitive decline and the onset of neurodegenerative changes in AD (Bell and Zlokovic 2009) . Presumably, AD-related BBB abnormality allows peripheral L5 into the brain which may enhance further pathology. Thus, the point to be concerned about is whether atherogenic L5 initiates or enhances inflammation-related neurodegeneration under the premise of impaired BBB (please also see Appendix S2 for supplementary discussion on apoB/LDL found in pathological CNS).
Several studies aiming at the cardiovascular effects of LDL (À) have been done. For example, LDL(À) promotes cytotoxicity and inflammatory cytokine secretion in vascular endothelial cells (De Castellarnau et al. 2000; Lu et al. 2009) ; also, such effects have been found in monocytes, macrophages, and lymphocytes (Benitez et al. 2007; Estruch Fig. 6 TAK-242 suppresses L5-induced apoptosis and necrosis in cultured BV-2 microglia. Cultures were pre-treated with or without TAK (0.5 or 5 lM) for 1 h and then incubated with L5 (30 lg/mL) for another 24 h. Untreated cultures were used as a control. Various assays including 3-(4, 5-dimethylthianol-2-yl)-2, 5 diphenyltetrazolium bromide reduction, analysis of nuclear morphology, and flow cytometry, were used to determine gliotoxicity (a), apoptotic nuclei (b and c), and cell death mode (d and e), respectively. Dense chromatin condensation and nuclei fragmentation are indicated by solid and broken arrows, respectively. Scale bar = 20 lm. The percentage of cells displaying apoptotic characteristics in different treatment groups is shown by a histogram (c). Both apoptotic and necrotic cells were assessed by FACS after staining with annexin-V-fluorescein-isothiocyanate (FITC)/ propidium iodide, and the histogram shows the cell percentage (% of total cells) of each death mode in different treatment groups (e). Data are presented as the mean AE SEM from at least three individual experiments performed in triplicate. *p < 0.05 versus control. et al. 2013a,b). These findings clearly support an atherogenic role for LDL(À). Nevertheless, the inflammatory role of LDL (À) in the progression of atherosclerosis-related neurological disorders has not been studied. We here pointed out that L5 positively impacts on microglial reactivity and neuronal death. Regrettably, the effects of LDL(À) on brain parenchyma remain unknown. Future in vivo work is needed to clarify this issue.
Regarding the release of cytokines, we found that L5 stimulates pro-inflammatory TNF-a release, but decreases the basal secretion of anti-inflammatory IL-10 from BV-2 microglia. Notably, the result obtained with IL-10 is in disagreement with Benitez et al. (2007) who study the effects of LDL(À) in monocytes. The exact cause for this incompatibility is unknown. A reasonable assumption is that although protein distribution discrepancies between L5 and L1 are largely compatible with those between LDL(À) and LDL(+) used by S anchez-Quesada group (Bancells et al. 2010) , several notable differences do exist (Ke et al. 2011) . First, the difference may be a result of the variations in different chromatographic separation methods. L5 is a product of the progressive increase in salt gradient during anion-exchange chromatography and represents a small but highly negatively charged LDL, whereas LDL(À) is a product of dichromatic division of total LDL. Second, a major difference between the L5/L1 and LDL(À)/LDL(+) pairs lies in their differential contents of apoE and apoAI. LDL(À) contains nearly fivefold of apoE and fourfold of apoAI in comparison with LDL(+); in contrast, L5 possesses 24-fold greater apoE and eightfold greater apoAI compared with L1. The third disparity is the presence of apo(a) in L5, whereas apo(a) is not detectable by ELISA in LDL(À). Fjcurther, the incompatibility may be ascribed to the differences in cell strain or in vitro culture system between Benitez et al. and our group (please also see Appendix S2 for supplementary discussion on IL-10).
Based on the work by Chen et al. (Tang et al. 2008; Lu et al. 2009 ), LOX-1 is considered to be a suitable cell surface receptor for L5 signaling. The binding of L5 to LOX-1 induces several biological effects, including apoptosis in cardiomyocytes and endothelial cells, chemokine release from endothelial cells, and endothelial LOX-1 up-regulation (Lu et al. 2009; Lee et al. 2012) . However, blockade of LOX-1 by a neutralizing anti-LOX-1 antibody did not suppress L5-induced inflammatory effects in BV-2 cells under our experimental conditions. According to accumulating studies related to modified LDL, inflammatory effects of L5 and LDL(À) are mediated separately by LOX-1 in L5 induces neuroinflammation via TLR4 in microgliaendothelial cells and by TLRs in immunocytes (i.e., monocytes and macrophages). No direct evidence until now indicates that either LOX-1 or TLR4 is a predominant receptor for the binding to modified LDL in microglia. Actually, LOX-1 in endothelial cells is a main scavenger receptor contributing to the formation of lipid-loaded foam cells in atherosclerotic lesions, whereas low LOX-1 expression is found in monocytes (Dunn et al. 2008) . Particularly, LOX-1 level decreases along with monocyte differentiation into macrophage (Yoshida et al. 1998) . Possibly, microglial LOX-1 expression is also less or inferior since microglia serves as the resident macrophages in the brain. Further, oxLDL, a typical ligand for LOX-1, does not compete with LDL(À) for binding to monocytes (Estruch et al. 2013a) , implying that oxLDL and LDL(À), respectively, bind to LOX-1 and TLRs in monocytes. The involvement of TLR4 in the biological effects of LDL(À) has been suggested (Faulin et al. 2010) and demonstrated in monocytes (Estruch et al. 2013a) . In line with these evidence, we considered that, like LDL(À) interacting with TLRs in monocytes, not LOX-1 but TLR4 is the major mediator of L5-induced neuroinflammation in microglia.
TLR4 is a major inducer of the inflammation that contributes to the progression of both atherosclerosis and neurodegeneration (Jin et al. 2008; Schoneveld et al. 2008) ; moreover, TLR4 activation is involved in cytokine increase in a transgenic mouse model of AD. TLR4 ligands, such as LPS and modified lipoproteins, directly binds to CD14 and induces intracellular signal transduction. The activation of the CD14/TLR4 in macrophages by modified LDL has been studied by Miller et al. (2003) , who showed that modified LDL binds to CD14, which promotes the association of CD14 with TLR4 and then stimulates phagocytosis, macropinocytosis, and cholesterol accumulation. Chavez- Sanchez et al. (2010a) showed that modified LDL induces inflammatory cytokine release, such as IL-1, IL-6, IL-10, and TNF-a, via CD14, TLR4, and TLR2 in monocytes/macrophages. Other studies in monocytes reported that oxLDL promotes MCP1 and IL-8 release and up-regulates TLR4 (Geng et al. 2010) ; LDL(À) binds to CD14/TLR4 and triggers production of the intracellular machinery for cytokine release (Estruch et al. 2013a) . On the basis of these evidence, the involvement of CD14/TLR4 in L5-induced neuroinflammation in microglia is considered feasible. Indeed, blocking TLR4 by TAK repressed L5-induced inflammatory episodes and apoptosis in BV-2 microglia, well indicating that L5 acts via TLR4 signaling. Noteworthily, there is an association between the tlr4 gene and susceptibility to sporadic AD (Minoretti et al. 2006) . TLR4-dependent TNF-a, IL-1b, IL-10, and IL-17 upexpression in AD mice has been reported (Jin et al. 2008) . Therefore, lowering plasma L5 levels or blocking microglial L5/TLR4 interactions in atherosclerotic patients is a viable strategy for reducing the risk for AD.
As illustrated by the effectiveness of relevant neutralizing antibody and signal pathway inhibitors, we postulate that ERK, JNK, p38, and PI3K/Akt are superior pathways responsible for L5/TLR4-driven inflammatory responses in BV-2 microglia. Our findings approximately confirm other studies highlighting that MAPKs and PI3K/Akt mediate inflammatory responses and microglial activation (Xie et al. 2004; Waetzig et al. 2005; Saponaro et al. 2012) . Since microglial NF-jB shows a minor association with L5/TLR4 signaling, which is peculiar from the studies describing the involvement of NF-jB in LDL(À)-mediated activation, we do not exclude the possibility that other kinases and transcription factors, such as IRAK and AP-1 (Buchanan et al. 2010; Okun et al. 2011) , join in L5/TLR4-induced inflammation (please also see Appendix S2 for supplementary discussion on NF-jB). In addition, p38 inhibits, ERK and NF-jB correlate nothing with, but JNK and PI3K promote L5-induced BV-2 cell apoptosis; dissimilarly, JNK, p38, and PI3K all potentiate co-cultured N2a cell damage mediated by L5-activated BV-2 microglia. Actually, MAPKs and PI3K engage in both pro-survival and pro-death processes in different experimental models (Berra et al. 1998; Hull et al. 2002; Sanchez et al. 2010 ). The precise mechanisms that determine the pro-survival or pro-death role of these kinases have not been clearly elucidated.
Concerning direct neurotoxicity of L5 to N2a cells, the neutralizing anti-LOX-1 antibody, but not TAK, effectively improved cell survival in L5-treated N2a cultures (Figure S6b) , suggesting that LOX-1 primarily mediates L5-induced N2a cell injury. Of note, TAK utterly blocked N2a cell survival decline in transwell co-cultures stimulated by L5, but not in L5-treated N2a cultures, hinting that N2a cell injury in a co-cultured BV-2/N2a system is majorly mediated by L5-induced BV-2 cell activation and neuroinflammation. We speculate that even if L5 reaches lower chamber through transwell membrane, its toxicity to cocultured N2a cells is minimal. It is likely that added L5 particles in upper chamber (transwell insert) are vastly uptaken by microglial pinocytosis, just like minimally oxidized LDL-induced, TLR4-and Syk-dependent macropinocytic uptake of a variety of lipoproteins in macrophages in hyperlipidemic environments (Miller et al. 2009; Kruth 2013) . Thus, a lesser L5 remnant occurring around cocultured N2a cells cannot produce a marked neurotoxicity (please also see Appendix S2 for supplementary discussion on L5-elicited BV-2 cell death).
Neuroinflammation is well-known to contribute to the pathophysiology of chronic neurodegeneration, including AD. For example, LPS-induced microglial activation and TNF-a/IL-1b release in rat hippocampus lead to glutamatergic transmission decline and subsequent learning and memory deficits (Tanaka et al. 2006) . LPS stimulation causes an overactivation of cultured rat microglia, leading to apoptotic death (Liu et al. 2001) . In neuron/glial co-cultures, LPS-activated microglia induce the apoptosis of primary neurons (Boje and Arora 1992) . Pro-inflammatory oxygen/nitrogen free radicals and cytokines are closely associated with brain cell apoptosis during neurodegeneration (Boje and Arora 1992; Liu et al. 2001; Brabers and Nottet 2006; Wang et al. 2014) . Similarly, we showed that L5 is directly toxic to N2a cells and creates neuroinflammatory stress via microglial activation, which indirectly causes the decrease of N2a cell viability in transwell co-cultures. Very likely, L5 is a harmful lipoprotein with dual threats; via inflammatory mechanisms, it peripherally promotes atherosclerosis and centrally contribute to neurodegeneration. Thus, elevated L5 in blood may represent the close association of CVDs, such as atherosclerosis, with cognitive decline.
In summary, this is the first study to identify a novel role of L5 as both neurotoxicant and neuroinflammatory stimulator. Growing evidence supports the strong association of atherosclerosis and proatherogenic risk factors with increased incidence of cognitive decline and AD. Here, we point out the possibility that human LDL(À), especially atherogenic L5, contributes to neuroinflammation-related neurodegenerative disorders, such as AD. Figure S4 . Both SP600125 and LY294002 decrease L5-induced apoptotic and necrotic cell death, where SB203580 increases apoptosis in cultured BV-2 microglia. Figure S5 . Blockade of LOX-1 by a neutralizing antibody diminishes oxLDL-induced, but not L5-induced, activation and cell death in cultured BV-2 microglia. Figure S6 . L5 is dose-dependently toxic to N2a cells and causes cell injury through LOX-1 signaling. Table S1 . An organized comparison between various signaling pathway inhibitors for L5-induced effect on inflammatory factors.
